177Lu-AB-3PRGD2 in Patients With Non Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-controlled, non-randomized study to assess the safety and measure
image-based absorbed dose of 177Lu-AB-3PRGD2 in patients with Non Small Cell Lung Cancerr
(NSCLC) who will undergo radioliagnd therapy using 177Lu-AB-3PRGD.